New combo shows promise for tough lymphomas

NCT ID NCT02213913

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested adding lenalidomide to a standard chemotherapy regimen (EPOCH-R) in 55 people with aggressive B-cell lymphomas linked to the MYC gene. The goal was to find the best dose and see if the combination improves how long patients live without their cancer getting worse. The trial is complete, and results help guide future treatment options.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

lenalidomide

What this could lead to

If successful, this combination could offer a more effective treatment option for aggressive B-cell lymphomas with MYC gene changes.

What could go wrong

This is an early-phase trial with only 55 participants, so results may not apply to all patients. Side effects from the chemotherapy combination can be severe.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for WALDENSTRÖM MACROGLOBULINEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell chronic lymphocytic leukemia B-cell non-Hodgkin lymphoma chronic lymphocytic leukemia/small lymphocytic lymphoma diffuse large B-cell lymphoma follicular lymphoma grade III lymphomatoid granulomatosis hairy cell leukemia high-grade B-cell lymphoma double-hit/triple-hit Hodgkin's lymphoma, mixed cellularity Hodgkins lymphoma intraocular lymphoma large-cell immunoblastic lymphoma Lymphoma, B-Cell, Marginal Zone MALT lymphoma mantle cell lymphoma marginal zone lymphoma nodal marginal zone B-cell lymphoma non-Hodgkin lymphoma primary cutaneous B-cell lymphoma small intestine lymphoma splenic marginal zone lymphoma testicular lymphoma Waldenstrom macroglobulinemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADULT GRADE III LYMPHOMATOID GRANULOMATOSIS B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA CONTIGUOUS STAGE II ADULT DIFFUSE LARGE CELL LYMPHOMA CONTIGUOUS STAGE II ADULT DIFFUSE MIXED CELL LYMPHOMA CONTIGUOUS STAGE II ADULT DIFFUSE SMALL CLEAVED CELL LYMPHOMA CONTIGUOUS STAGE II ADULT IMMUNOBLASTIC LARGE CELL LYMPHOMA CONTIGUOUS STAGE II GRADE 1 FOLLICULAR LYMPHOMA CONTIGUOUS STAGE II GRADE 2 FOLLICULAR LYMPHOMA CONTIGUOUS STAGE II GRADE 3 FOLLICULAR LYMPHOMA CONTIGUOUS STAGE II MANTLE CELL LYMPHOMA CONTIGUOUS STAGE II MARGINAL ZONE LYMPHOMA CONTIGUOUS STAGE II SMALL LYMPHOCYTIC LYMPHOMA CUTANEOUS B-CELL NON-HODGKIN LYMPHOMA EXTRANODAL MARGINAL ZONE B-CELL LYMPHOMA OF MUCOSA-ASSOCIATED LYMPHOID TISSUE INTRAOCULAR LYMPHOMA NODAL MARGINAL ZONE B-CELL LYMPHOMA NONCONTIGUOUS STAGE II ADULT DIFFUSE LARGE CELL LYMPHOMA NONCONTIGUOUS STAGE II ADULT DIFFUSE MIXED CELL LYMPHOMA NONCONTIGUOUS STAGE II ADULT DIFFUSE SMALL CLEAVED CELL LYMPHOMA NONCONTIGUOUS STAGE II ADULT IMMUNOBLASTIC LARGE CELL LYMPHOMA NONCONTIGUOUS STAGE II GRADE 1 FOLLICULAR LYMPHOMA NONCONTIGUOUS STAGE II GRADE 2 FOLLICULAR LYMPHOMA NONCONTIGUOUS STAGE II GRADE 3 FOLLICULAR LYMPHOMA NONCONTIGUOUS STAGE II MANTLE CELL LYMPHOMA NONCONTIGUOUS STAGE II MARGINAL ZONE LYMPHOMA NONCONTIGUOUS STAGE II SMALL LYMPHOCYTIC LYMPHOMA PROGRESSIVE HAIRY CELL LEUKEMIA, INITIAL TREATMENT SMALL INTESTINE LYMPHOMA SPLENIC MARGINAL ZONE LYMPHOMA STAGE 0 CHRONIC LYMPHOCYTIC LEUKEMIA STAGE I ADULT DIFFUSE LARGE CELL LYMPHOMA STAGE I ADULT DIFFUSE MIXED CELL LYMPHOMA STAGE I ADULT DIFFUSE SMALL CLEAVED CELL LYMPHOMA STAGE I ADULT HODGKIN LYMPHOMA STAGE I ADULT IMMUNOBLASTIC LARGE CELL LYMPHOMA STAGE I CHRONIC LYMPHOCYTIC LEUKEMIA STAGE I GRADE 1 FOLLICULAR LYMPHOMA STAGE I GRADE 2 FOLLICULAR LYMPHOMA STAGE I GRADE 3 FOLLICULAR LYMPHOMA STAGE I MANTLE CELL LYMPHOMA STAGE I MARGINAL ZONE LYMPHOMA STAGE I SMALL LYMPHOCYTIC LYMPHOMA STAGE II ADULT HODGKIN LYMPHOMA STAGE II CHRONIC LYMPHOCYTIC LEUKEMIA STAGE II SMALL LYMPHOCYTIC LYMPHOMA STAGE III ADULT DIFFUSE LARGE CELL LYMPHOMA STAGE III ADULT DIFFUSE MIXED CELL LYMPHOMA STAGE III ADULT DIFFUSE SMALL CLEAVED CELL LYMPHOMA STAGE III ADULT HODGKIN LYMPHOMA STAGE III ADULT IMMUNOBLASTIC LARGE CELL LYMPHOMA STAGE III CHRONIC LYMPHOCYTIC LEUKEMIA STAGE III GRADE 1 FOLLICULAR LYMPHOMA STAGE III GRADE 2 FOLLICULAR LYMPHOMA STAGE III GRADE 3 FOLLICULAR LYMPHOMA STAGE III MANTLE CELL LYMPHOMA STAGE III MARGINAL ZONE LYMPHOMA STAGE III SMALL LYMPHOCYTIC LYMPHOMA STAGE IV ADULT DIFFUSE LARGE CELL LYMPHOMA STAGE IV ADULT DIFFUSE MIXED CELL LYMPHOMA STAGE IV ADULT DIFFUSE SMALL CLEAVED CELL LYMPHOMA STAGE IV ADULT HODGKIN LYMPHOMA STAGE IV ADULT IMMUNOBLASTIC LARGE CELL LYMPHOMA STAGE IV CHRONIC LYMPHOCYTIC LEUKEMIA STAGE IV GRADE 1 FOLLICULAR LYMPHOMA STAGE IV GRADE 2 FOLLICULAR LYMPHOMA STAGE IV GRADE 3 FOLLICULAR LYMPHOMA STAGE IV MANTLE CELL LYMPHOMA STAGE IV MARGINAL ZONE LYMPHOMA STAGE IV SMALL LYMPHOCYTIC LYMPHOMA TESTICULAR LYMPHOMA UNTREATED HAIRY CELL LEUKEMIA WALDENSTRÖM MACROGLOBULINEMIA

Contacts and locations

Locations

  • Decatur Memorial Hospital Cancer Care Institute

    Decatur, Illinois, 62526, United States

  • Illinois Cancer Care

    Peoria, Illinois, 61615, United States

  • NorthShore University HealthSystem

    Evanston, Illinois, 60201, United States

  • Rush University Medical Center

    Chicago, Illinois, 60612, United States

  • University of Chicago

    Chicago, Illinois, 60637, United States

  • University of Maryland

    Baltimore, Maryland, 21202, United States